nctId: NCT06295692 id: 77242113PSO3005 id: 77242113PSO3005 type: OTHER domain: Janssen Pharmaceutical K.K. briefTitle: A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis overallStatus: RECRUITING date: 2024-02-09 date: 2025-02-19 date: 2027-12-23 date: 2024-03-06 date: 2024-04-25 name: Janssen Pharmaceutical K.K. class: INDUSTRY briefSummary: The purpose of this study is to evaluate how effective JNJ-77242113 is in participants with generalized pustular psoriasis (GPP) or erythrodermic psoriasis (EP). conditions: Generalized Pustular Psoriasis conditions: Erythrodermic Psoriasis studyType: INTERVENTIONAL phases: PHASE3 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 16 type: ESTIMATED name: JNJ-77242113 measure: Percentage of Participants With Generalized Pustular Psoriasis (GPP) who Experience Treatment Success Based on Clinical Global Impression (CGI) Scale According to Japanese Dermatological Association (JDA) Total Score at Week 16 measure: Percentage of Participants With Erythrodermic Psoriasis (EP) who Experience Treatment Success Based on CGI Scale at Week 16 measure: Percentage of Participants With GPP who Experience Treatment Success Based on CGI Scale According to JDA Total Score Over Time measure: Percentage of Participants With EP who Experience Treatment Success Based on CGI Scale Over Time measure: Change From Baseline in Total Score of JDA Severity Index for GPP measure: Change From Baseline in Severity Classification of JDA Severity Index for GPP measure: Change From Baseline in Body Surface Area (BSA) for EP measure: Percentage of Participants who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) measure: Percentage of Participants who Achieve an IGA Score of Cleared (0) measure: Percent Improvement From Baseline in Psoriasis Area and Severity Index (PASI) measure: Change From Baseline in Dermatology Life Quality Index (DLQI) Score measure: Percentage of Participants who Achieve a DLQI Score of 0 or 1 measure: Change From Baseline in EuroQol-5 Dimension 5-Level (EQ-5D-5L) measure: Percentage of Participants With Adverse Events (AEs) and Serious AEs sex: ALL minimumAge: 12 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: JR Sapporo Hospital status: RECRUITING city: Hokkaido zip: 060-0033 country: Japan lat: 43.41104 lon: 142.88878 facility: Ichinomiya Municipal Hospital status: RECRUITING city: Ichinomiya zip: 491-8558 country: Japan lat: 35.3 lon: 136.8 facility: Teikyo University Hospital status: RECRUITING city: Itabashi Ku zip: 173 8606 country: Japan lat: 35.74893 lon: 139.71497 facility: Hospital of the University of Occupational and Environmental Health status: RECRUITING city: Kitakyushu-shi zip: 807-8556 country: Japan lat: 33.85181 lon: 130.85034 facility: Kumamoto University Hospital status: RECRUITING city: Kumamoto zip: 860-8556 country: Japan lat: 32.80589 lon: 130.69182 facility: Nagoya City University Hospital status: RECRUITING city: Nagoya zip: 467 8602 country: Japan lat: 35.18147 lon: 136.90641 facility: Public Interest Incorporated Foundation Nipoon Life Saiseikai Nippon Life Hospital status: RECRUITING city: Osaka zip: 550 0006 country: Japan lat: 34.69374 lon: 135.50218 facility: Tohoku University Hospital status: RECRUITING city: Sendai zip: 980-8574 country: Japan lat: 38.26667 lon: 140.86667 facility: Dokkyo Medical University Hospital status: RECRUITING city: Shimotsuga Gun zip: 321-0293 country: Japan facility: Tokyo Medical University Hospital status: RECRUITING city: Shinjuku zip: 160-0023 country: Japan lat: 35.2946 lon: 139.57059 facility: Fujita Health University Hospital status: RECRUITING city: Toyoake zip: 470-1192 country: Japan lat: 35.038 lon: 136.99931 facility: Mie University Hospital status: RECRUITING city: Tsu zip: 514 8507 country: Japan lat: 34.73333 lon: 136.51667 hasResults: False